Cite
HARVARD Citation
Dimopoulos, M. et al. (2018). Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4‐year follow‐up and analysis of relative progression‐free survival from the randomized ELOQUENT‐2 trial. Cancer. 124 (20), pp. 4032-4043. [Online].